Nav: Home

Study examines melanoma incidence, death

December 21, 2016

A new research letter published online by JAMA Dermatology updates information on trends in melanoma incidence and death in the United States since 2009.

Alex M. Glazer, M.D., of the National Society for Cutaneous Medicine, New York, and coauthors report an estimated 76,380 Americans will be diagnosed with melanoma in 2016. They note that:
  • Incidence rates per 100,000 population have grown from 22.2 to 23.6.
  • Current lifetime risk of an American developing invasive melanoma is 1 in 54 compared with 1 in 58 when the authors reported in 2009.
  • Risk of early stage in situ melanoma has risen from 1 in 78 in 2009 to 1 in 58 now.
  • Lifetime risk of being diagnosed with invasive or in situ melanoma is now 1 in 28.
  • The current estimate is that 10,130 Americans will die from melanoma in 2016, up from 8,650 in 2009.

"The overall burden of disease for melanoma is increasing and rising rates are not simply artifact owing to increased detection of indolent disease," the article concludes.
-end-
(JAMA Dermatology. Published online December 21, 2016. doi:10.1001/jamadermatol.2016.4512; available pre-embargo at the For The Media website.)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

To place an electronic embedded link in your story: Links will be live at the embargo time: http://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2016.4512

The JAMA Network Journals

Related Melanoma Articles:

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.
Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.
Describing aspects of melanoma progression
Three related articles and an editorial focus on various aspects of melanoma progression.
Is your melanoma hot enough for immunotherapy?
University of Colorado Cancer Center study presented at AACR 2019 shows that tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent.
BU researchers discover therapeutic target of melanoma
Researchers have identified a biomarker and a possible new therapy for melanoma.
More Melanoma News and Melanoma Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...